#USA #Houston #Myeloproliferative Neoplasms #Jubilant Therapeutics #JBI-802

Jubilant Therapeutics Shares Groundbreaking Results from Phase 1/2 Study of JBI-802

Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for hematological malignancies, presented compelling preliminary data from their ongoing Phase 1/2 study of JBI-802 at the recent Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston, Texas. This meeting, which took place from September 9 to 12, highlighted the company's groundbreaking work on a promising dual inhibitor designed to target various myeloproliferative neoplasms (MPNs).

The findings presented demonstrated JBI-802's significant potential in treating conditions such as essential thrombocythemia (ET) and polycythemia vera (PV), blood cancers characterized by excessive blood cell production driven by mutations in critical genes. With twelve patients evaluated across four dosage levels, remarkable results were visible, showcasing the drug’s capacity to reduce platelet levels rapidly and significantly.

Clinical Highlights

The study's dose-escalation phase included patients administered with 5 mg, 7 mg, 15 mg, and 20 mg of JBI-802. Among the many key observations:
1. Efficacy Across Conditions: Reduction in platelet counts was recorded across all patient subtypes, including ET, PV, myelofibrosis (MF), and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). All patients carrying mutations in JAK2, CALR, and MPL witnessed clinical improvement.
2. Strong Day-One Results: Notably, patients on the 15 mg dosage showed substantial platelet reductions of up to 81% within the initial 30 days. Furthermore, all evaluated ET/PV patients observed decreases in platelet counts ranging from 36% to 91%.
3. Durability of Response: Even with modifications in dosing, the platelet responses remained stable, demonstrating JBI-802's controllable pharmacokinetic-pharmacodynamic relationship, which is crucial for effective long-term treatment.

Safety Profile

As of the last data cutoff on June 30, 2026, the safety findings were equally encouraging. No dose-limiting toxicities were observed across the lower dosage levels, and the sole dose-limiting event at 20 mg was effectively managed through protocol-defined adjustments. Among treatment-emergent adverse events (TEAEs), most were mild, confirming JBI-802's tolerability and safety in the ongoing study.

Daniel O’Connor, President and CEO of Jubilant Therapeutics, commented: “These initial findings signify important strides in managing myeloproliferative neoplasms. We are particularly thrilled with the rapid and sustained reductions in platelet counts across various MPN subtypes, combined with a favorable tolerability profile.”

The Future of JBI-802

JBI-802 emerges as a uniquely innovative oral dual inhibitor of lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6), an approach not previously adopted in other treatments. The clinical study aims to pursue safety, tolerability, optimal Phase 2 dosage, and preliminary efficacy evaluations through platelet feedback and molecular response metrics.

The mechanism involves simultaneous action on critical pathways related to abnormal blood cell production, potentially leading to better outcomes than single-target treatments.

Enrollment in the study has not yet concluded, and Jubilant Therapeutics anticipates sharing further efficacy and safety data as the trials progress.

The implications for patients suffering from myeloproliferative neoplasms are significant, as current therapies often fail to achieve satisfactory results. Through JBI-802, Jubilant Therapeutics is poised to deliver a transformative treatment option, highlighting the urgent need for innovation in hematological care.

For complete details on the study's methodologies and results, visit Jubilant's official presentation available at the SOHO 2026 website.